Thank you, Mr. Chair.
Thank you, witnesses, for sharing your stories.
As my colleagues have already said, I think everybody around the table can agree, across party lines, that when we hear more of the patient experience, it definitely gives us an opportunity to try to go back to the table and fix some of the—I hate to say it—more common sense things that need to be fixed in government bureaucracy.
Ms. Little, your story is one we hear too often, not just in the medical scenario but in a lot of scenarios in which the government makes things more complicated than they need to be when people are just trying to help their children or help vulnerable people in our communities.
I wanted to ask, along Mr. Davies' line of questioning, about the cost of the two drugs and the fact that this new drug has this time release formula in it and, because of that, it's become so much more expensive. You may not have the data, but how many people have this type of rare disease in Canada? I know it impacts children, mostly.